Synthetic blood vessels and uses thereof

• US 10,451,637 B2
• Filed: 03/26/2018
• Issued: 10/22/2019
• Est. Priority Date: 03/24/2017
• Status: Active Grant

• Current Assignee: University of British Columbia
• Original Assignee: University of British Columbia
• Inventors: Wellington, Cheryl, Robert, Jerome
• Primary Examiner(s): Gudibande, Satyanarayana R
• Application Number:
  US15/935,820
• Publication Number:
  US 20180275147A1
• Time in Patent Office: 575 Days
• Field of Search: None
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/5058 Neurological cells
• CPC Class Codes: G01N 33/5061 Muscle cells
• CPC Class Codes: G01N 33/5064 Endothelial cells
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention provides a synthetic blood vessel and use thereof in drug screening, drug delivery and prognoses of cerebrovascular dysfunction.

Claims

1. A method of determining the risk for a cerebrovascular dysfunction in a subject in need thereof comprising:

i) providing a synthetic blood vessel;

ii) providing an Aβ

peptide;

iii) contacting the synthetic blood vessel with a sample from the subject; and

iv) determining the level of Aβ

deposition or transport in the sample,

wherein the subject has an increased risk for a cerebrovascular dysfunction if the level of Aβ

deposition is increased or if Aβ

transport is reduced.

2. The method of claim 1 further comprising monitoring the risk for the cerebrovascular dysfunction.

3. The method of claim 1 wherein the sample comprises HDL or apoE or a combination thereof.

4. The method of claim 2 further comprising providing a monocyte cell and determining the level of monocyte adhesion.

5. The method of claim 3 further comprising determining the level of endothelial cell activation.

6. The method of claim 1 wherein the cerebrovascular dysfunction is type II diabetes mellitus, hypercholesterolemia, hypertension, cerebral amyloid angiopathy (CAA), ischemic brain injury, stroke, dementia, cognitive impairment and Alzheimer'"'"'s disease.

7. The method of claim 1 wherein the subject is a human.